Single-dose escalation study of yogliptin in healthy Chinese volunteers.
CONCLUSION: Yogliptin was well tolerated in healthy subjects, with no dose-limiting toxicity observed in the range from 2.5 to 600 mg. Yogliptin inhibited plasma DPP-4 activity for 72 h at single doses of 25-200 mg and for 1 week at 400 mg, suggesting that once-weekly dosing of yogliptin is possible in type 2 diabetes patients.
TRIAL REGISTRATION: ChiCTR-IIR-17010311 (Chictr.org).
PMID: 31173870 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Gou ZP, Wang ZL, Liang XF, Zheng L, Wang Y, Feng P Tags: Eur J Pharm Sci Source Type: research
More News: China Health | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Study | Toxicology